Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
Alexion Pharmaceuticals, Inc. · Transthyretin Amyloid Cardiomyopathy
Phase 3
Active, not recruiting
1,181
2026-02
Industry sponsor intelligence
Alexion Pharmaceuticals, Inc.Clinical Pipeline.
Lead-sponsor view of Alexion Pharmaceuticals, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 1
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 1,181
Pipeline overview
Programs by phase and activity.
Velocity
Alexion Pharmaceuticals, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Nesiritide → | 1 | 0 | 0 | 1 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Alexion Pharmaceuticals, Inc. studies.
This page groups studies where Alexion Pharmaceuticals, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates